Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer

chemotherapy (CDDP, 5-FU) plus radiation therapy in treating patients with unresectable, advanced or recurrent esophageal cancer.

metastasis
measurable disease
cancer
VEGFR2
vaccine therapy
  • 11 views
  • 07 Nov, 2020
  • 1 location
Phase / Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer

CpG7909 in patients with advanced or recurrent esophageal cancer.

measurable disease
cancer
metastatic esophageal cancer
platelet count
recurrent esophageal cancer
  • 5 views
  • 07 Nov, 2020
  • 1 location
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors Lymphomas or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic …

prednisone
gnrh
major surgery
metastatic disease
fgfr inhibitor azd4547
  • 6093 views
  • 07 Sep, 2021
  • 1028 locations
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

This is a randomized, controlled, multi-center, open trial, unresectable locally advanced or metastatic esophageal squamous cell carcinoma patients that failed at least second-line treatment and overexpressed EGFR were enrolled and randomly assigned to the experimental group and control group at a 1: 1 ratio.,who received Larotinib and the chemotherapy regimen …

EGFR
carcinoma
potassium
irinotecan
esophagus cancer
  • 0 views
  • 17 Jul, 2021
  • 2 locations
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

This phase I/II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other places in the body (metastatic), has come back (recurrent), or cannot be removed …

adenocarcinoma
neutrophil count
metastasis
measurable disease
ejection fraction
  • 83 views
  • 05 Jul, 2021
  • 25 locations